LaineL. Upper gastrointestinal tract hemorrhage. West JMed1991; 155: 274–9.
2.
The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med1988; 319: 983–9.
3.
GroszmannRJ, BoschJ, GraceNDHemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology1990; 99: 1401–7.
4.
LebrecD, PoynardT, BernuauJA randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology1984; 4: 355–8.
5.
ColomboM, De FranchisR, TommasiniM, SangiovanniA, DioguardiN. Beta blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: A multicenter randomized controlled trial. Hepatology1989; 9: 433–8.
6.
GardenOJ, MillsPR, BirnieGG, MurrayGD, CarterDC. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. Gastroenterology1990; 98: 185–90.
7.
GardenOJ, MotylH, GilmourWHPrediction of outcome following acute variceal haemorrhage. Br J Surg1985; 72: 91–5.
8.
WilliamsSGJ, WestabyD. Management of variceal hemorrhage. Br Med J1994; 308: 1213–7.
9.
UenoT, InuzukaS, TorimuraTDistribution of substance P and vasoactive intestinal peptide in the human liver: light and electron immunoperoxidase methods of observation. Am J Gastroenterol.1991; 86: 1633–7.
10.
FeherE, FodorM, FeherJ. Ultrastructural localization of somatostatin -and substance P- immunoreactive nerve fibre in the feline liver. Gastroenterology1992; 102: 287–94.
11.
IrleC, KocherO, CabbianiG.Contractility of myofibroblasts during experimental liver cirrhosis. J Submicrosc Cytol Pathol.1980; 12: 209–17.
12.
TsaiYT, LinHC, YangMCMPlasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function. J. Hepatol.1995; 23: 681–88.
13.
AsbertM, GinesA, GinesPCirculating level of endothelin in cirrhosis. Gastroenterology1993; 104: 1485–91.
14.
RockeyDC, WeisigerRA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implication for regulation of portal pressure and resistance. Hepatology1996; 24: 233–40.
15.
PolioJ, GroszmannRJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis1986; 6: 318–31.
16.
LebrecD, De FleuryP, RueffB, NahumH, BenhamouJP. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology1980; 79: 1139–44.
17.
TsaoG Garcia, GroszmannRJ, FisherRLPortal pressure, presence of gastrointestinal varices and variceal bleeding. Hepatology1985; 5: 419–24.
18.
KravetzD, BoschJ, ArderiuMHemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: Influence of the extent of portal-systemic shunting. Hepatology1989; 9: 808–14.
19.
BernardB, CadranelJ-F, VallaDPrognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology1995; 108: 1828–34.
20.
GoulisJ, ArmonisA, PatchD, SabinC. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology1998; 27: 1207–12.
21.
BernardB, GrangeJ-D, NyugenK E, XavierA, PierreO, ThierryP. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology1999; 29: 1655–61.
22.
JalanR, HayesPC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut2000; 46: iii1–iii15.
23.
Rodriguez-PerezF, GroszmannRJ. Pharmacologic treatment of portal hypertension. Gastroenterol Clin North Am1992; 21: 15–40.
24.
FreemanJG, CobdenMD, RecordCO. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. J Clin Gastroenterol1989; 11: 58–60.
EscorsellA, del ArbolL Ruiz, PlanasRMulticenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: The TEST study. Hepatology2000; 32: 471–6.
27.
FeuF, del ArbolL Ruiz, BanaresR, BoschJ. Double blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Gastroenterology1996; 111: 1291–9.
28.
loannouG, DoustJ, RockeyDC. Terlipressin for acute esophageal variceal hemorrhage (Cochrane Review). Cochrane Database of Systematic Reviews(1):CD002147, 2003.
29.
JenkinsSA, ShieldsR, DaviesMA multicentre randomized trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut1997; 41: 526–33.
30.
BessonI, IngrandP, PersonBSclerotherapy with or without octreotide for acute variceal bleeding. N Eng j Med1995; 333: 550–60.
31.
SungJJ, ChungSC, YungMY. Prospective randomized study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet1995; 346: 1666–9.
32.
EscorsellA, BandiJC, AndreuVDesensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology2001; 120: 161–9.
33.
BurroughsAK. Double blind randomized clinical trial of 5 day octreotide versus placebo associated sclerotherapy for treatment failures. Hepatology1996; 24: 901.
34.
WestabyD, HayesPC, GimsonAE, PolsonRJ, WilliamsR. Controlled clinical trial of injection sclerotherapy for active variceal bleeding. Hepatology1989; 9: 274–7.
35.
LoGH, LaiKH, NgWWInjection sclerotherapy preceded by esophageal tamponade versus immediate sclerotherapy in arresting active variceal bleeding: a prospective randomized trial. Gastrointest Endosc1992; 38: 421–4.
36.
LoGH, LaiKH, ChengJS. Emergency Banding ligation versus sclerotherapy for the controlled bleeding of esophageal varices. Hepatology1997; 25: 1101–4.
37.
StiegmannGV, GoffJS, Michaletz-OnodyPA. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med1992; 326: 1527–32.
38.
FortE, SautereauD, SilvainC, IngrandP, PilligandB, BeauchantM. A randomized trial of terlipressin plus nitroglycerine vs. balloon tamponade in the acute variceal bleeding. Hepatology1990; 11: 678–81.
39.
ChojkierM, ConnHO. Esophageal tamponade in the treatment of bleeding varices. A decadal progress report. Dig Dis Sci1980; 25: 267–72.
40.
AzoulayD, CastaingD, MajnoPSalvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol2001; 35: 590–7.
SanyalAJ, FreedmanAM, LuketicVATransjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology1996; 111: 138–46.
43.
JalanR, JohnTG, ReadheadDNA comparative study of emergency transjugular intrahepatic portosystemic stent-shunt and esophageal transection in the management of uncontrolled variceal hemorrhage. Am J Gastroenterol1995; 90: 1932–7.
44.
SarinSK, LahotiD, SaxenaSPPrevalence, classification and natural history of gastric varices: a long term follow up study in 568 portal hypertension patients. Hepatology1992; 16: 1343–9.
ChiuKW, ChangchienCS, ChuahSKEndoscopic injection sclerotherapy with 1.5% sotradecol for bleeding cardiac varices. J Clin Gastroenterol1997; 24: 161–4.
47.
OgawaK, IshikawaS, NaritakaYClinical evaluation of endoscopic injection sclerotherapy using N-butyl-2-cyanoacrylate for gastric variceal bleeding. J Gastroenterol Hepatol1999; 14: 245–50.
48.
BarangeK, PeronJM, ImaniKTransjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology1999; 30 (5): 1139–43.
49.
StanleyAJ, JalanR, IrelandHM, RedheadDN, BouchierIA, HayesPC. A comparison between gastric and oesophageal variceal haemorrhage treated with transjugular intrahepatic portosystemic stent shunt (TIPSS). Aliment Pharmacol Ther1997; 11: 171–6.
50.
TripathiD, HelmyA, MacbethKTen years follow-up of 472 patients following transjugular intrahepatic portosystemic stent-shunt insertion at a single centre. Euro J of Gastroenterol and Hepatol2004; 16 (1): 9–18.
51.
LoGH, LaiKH, ChengJS, ChenMH, ChiangHT. A prospective randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology2001; 33: 1060–4.
52.
YangWL, TripathiD, TherapondosG, ToddA, HayesPC. Endoscopic use of human thrombin in bleeding gastric varices. AmJ Gastroenterol2002; 97: 1381–5.
MatsumotoA, HamamotoN, NomuraTBalloon-occluded retrograde transvenous obliteration of high risk gastric fundal varices. Am J Gastroenterol1999; 94: 643–9.
56.
ChoiYH, YoonCJ, ParkJH, ChungJW, KwonJW, ChoiGM. Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunts. Korean Journal of Radiology2003; 4: 109–16.
57.
GrahamDY, SmithJL. The course of patients after variceal hemorrhage. Gastroenterology1981; 80: 800–9.
58.
SmithJL, GrahamDY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology1982; 82: 968–73.
59.
de FranchisR, PrimiganiM. Why do varices bleed?Gastroenterol Clin North Am1992; 21: 85–101.
60.
BernardB, LebrecD, MathurinP, OpolonP, PoynardT. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology1997; 25: 63–70.
61.
GournayJ, MasliahC, MartinT, PerrinD, GalmicheJP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal bleeding. Hepatology2000; 31: 1239–45.
62.
VillanuevaC, BalanzoJ, NovellaMTNadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Eng J Med1996; 334: 1624–9.
63.
BureauC, PeronJM, AlricL“A La Carte” treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Gastroenterology2003; 124: 1993–5. (comment)
64.
D'AmicoG, PagliaroL, BoschJ. The treatment of portal hypertension: a meta-analytic review. Hepatology1995; 22: 332–54.
65.
BernardB, LebrecD, MathurinP, OpolonP, PoynardT. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol1997; 26: 312–24.
66.
LoGH, LaiKH, ChengJSA prospective randomized trial of sclerotherapy vs. ligation in the management of bleeding esophageal varices. Hepatology1995; 22: 466–71.
67.
LaineL, CookD. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med1995; 123: 280–7.
68.
LoGH, ChenWC, ChenMHBanding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology2002; 123 (3): 728–34.
69.
PatchD, SabinCA, GoulisJA randomized controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology2002; 123 (4): 1013–9.
70.
VillanuevaC, MinanaJ, OritzJEndoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Eng J Med2001; 345: 647–55.
71.
VinelJP, LamouliatteH, CalesPPropranolol reduces the rebleeding rate during endoscopic sclerotherapy before variceal obliteration. Gastroenterology1992; 102: 1760–3.
72.
AvgerinosA, RekoumisG, KlonisCPropranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy: a randomized controlled trial. J Hepatol1993; 19: 301–11.
73.
LoG-H, LaiK-H, ChengJ-SBeta adrenergic antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: an analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Eng J Med1991; 324: 1532–8.
74.
PagliaroL, D'AmicoG, SrensenTIPrevention of first bleeding in cirrhosis: a meta-analysis of randomized trials of nonsurgical treatment. An Intern Med1992; 117: 59–70.
75.
TeranJC, ImperialeTF, MullenKD, TavillAS, McCulloughAJ. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Gastroenterology1997; 112; 473–82.
76.
Garcia-PaganJC, FeuF, BoschJ, RodesJ. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: a randomized controlled study. Ann Intern Med1991; 114: 869–73.
77.
Garcia-PaganJ, VillanuevaC, VilaMIsosorbide mononitrate in the prevention of first variceal bleed in patients who cannot tolerate beta blockers. Gastroenterology2001; 121: 908–14.
78.
LuiHF, StanleyAJ, ForrestEHPrimary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology2002; 123: 735–44.
79.
ImperialeT, ChalasaniN. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology2001; 33: 802–7.